Who is sponsoring NCT03104907?

NCT03104907 is sponsored by Rigshospitalet, Denmark.

What drugs are being tested in NCT03104907?

Interventions in NCT03104907: Prostatic Artery Embolization.

What condition does NCT03104907 study?

NCT03104907 studies Prostatic Neoplasm, Lower Urinary Tract Symptoms, Urological Manifestations, Prostatic Diseases.

Is NCT03104907 still recruiting?

NCT03104907 is currently completed. Last updated 29 November 2018.

Last reviewed 2018-11-29 · How we verify

NCT03104907

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prostatic Artery Embolization for Obstructive Uropathy Due to Prostate Cancer

Completed NA Last updated 29 November 2018

What this trial tests

NA trial testing Prostatic Artery Embolization in Prostatic Neoplasm in 15 participants. Completed in 27 November 2018.

Timeline

22 March 2017

Primary endpoint
27 November 2018

27 November 2018

Quick facts

Lead sponsor	Rigshospitalet, Denmark
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	22 March 2017
Primary completion	27 November 2018
Estimated completion	27 November 2018
Sites	1 location across Denmark

Drugs / interventions tested

Prostatic Artery Embolization

Conditions studied

Prostatic Neoplasm — all drugs for Prostatic Neoplasm →
Lower Urinary Tract Symptoms — all drugs for Lower Urinary Tract Symptoms →
Urological Manifestations — all drugs for Urological Manifestations →
Prostatic Diseases — all drugs for Prostatic Diseases →

Sponsor

Rigshospitalet, Denmark

Who can join

Eligibility, male only, with Prostatic Neoplasm or Lower Urinary Tract Symptoms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to investigate the safety and efficacy of prostatic artery embolization of patients with recurrent symptoms secondary to locally advanced prostatic cancer including pelvic pain, bleeding or need for permanent urinary catheter who are unfit for or refuse surgical treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series.
Malling B, Røder MA, Lindh M, Frevert S, et al · · 2019 · cited 17× · PMID 31062066 · DOI 10.1007/s00270-019-02227-4
Effectiveness and Safety of Prostatic Artery Embolization for Patients with Prostate Cancer: A Systematic Review and Meta-Analysis.
Lucas-Cava V, Sánchez-Margallo FM, Sun F. · · 2025 · PMID 40640416 · DOI 10.1007/s00270-025-04107-6

Verify or expand the search:

Other trials of Prostatic Artery Embolization

Trials testing the same drug.

NCT07416227 — Comparison Between Water Vapor Thermal Therapy and Prostatic Artery Embolization in Treatment of Benign Prostatic Hyperp · NA · recruiting
NCT03372096 — LC Bead LUMI for Prostatic Artery Embolization · NA · completed
NCT03457805 — Prostatic Artery Embolization in Advanced Prostate Cancer · NA · unknown
NCT03099421 — Prostatic Artery Embolization for Benign Prostatic Obstruction · NA · completed

Other recruiting trials for Prostatic Neoplasm

Currently open trials in the same condition.

NCT07084779 — Investigation of Impact of AI on Prostate Cancer Workflow · NA · recruiting
NCT05968144 — Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness · Phase 1, PHASE2 · active not recruiting
NCT05849298 — A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC · Phase 2 · active not recruiting
NCT06292897 — Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression · recruiting
NCT06046131 — Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression. · NA · recruiting

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03104907 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
Last refreshed: 29 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03104907.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing